Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML.

J Transl Med. 2018 Jun 29;16(1):179. doi: 10.1186/s12967-018-1552-1.

2.

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML.

J Transl Med. 2018 May 29;16(1):142. doi: 10.1186/s12967-018-1507-6. Erratum in: J Transl Med. 2018 Jun 29;16(1):179.

3.

Olfactory stimulation or inhibition of sexual behavior of stallions in non-breeding season.

Guillaume D, Moussu C, de Geoffroy F, Chesneau D, Keller M.

Physiol Behav. 2018 Mar 15;186:1-9. doi: 10.1016/j.physbeh.2017.12.031. Epub 2017 Dec 26.

PMID:
29287623
4.

Isolated CNS Hodgkin's lymphoma: implications for tissue diagnosis.

Martinez DL, Gujrati M, Geoffroy F, Tsung AJ.

CNS Oncol. 2014 Nov;3(6):383-7. doi: 10.2217/cns.14.45.

PMID:
25438809
5.

A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775.

Kottschade LA, Suman VJ, Perez DG, McWilliams RR, Kaur JS, Amatruda TT 3rd, Geoffroy FJ, Gross HM, Cohen PA, Jaslowski AJ, Kosel ML, Markovic SN.

Cancer. 2013 Feb 1;119(3):586-92. doi: 10.1002/cncr.27760. Epub 2012 Aug 22.

6.

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.

Friday BB, Anderson SK, Buckner J, Yu C, Giannini C, Geoffroy F, Schwerkoske J, Mazurczak M, Gross H, Pajon E, Jaeckle K, Galanis E.

Neuro Oncol. 2012 Feb;14(2):215-21. doi: 10.1093/neuonc/nor198. Epub 2011 Nov 16.

7.

Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton RF, Rowland KM Jr, Mischel P, Yong WH, Scheithauer BW, Schiff D, Giannini C, Buckner JC; North Central Cancer Treatment Group Study N0177.

J Clin Oncol. 2008 Dec 1;26(34):5603-9. doi: 10.1200/JCO.2008.18.0612. Epub 2008 Oct 27.

8.

Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial of the North Central Cancer Treatment Group.

Dy GK, Jett JR, Geoffroy FJ, Krewer KD, Tazelaar H, Maurer M, Rowland K, Mailliard J, Krook J, Dakhil S, Kutteh L, Kugler J, Wender D.

J Thorac Oncol. 2006 Mar;1(3):211-7. No abstract available.

9.

Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.

Krishnan S, Brown PD, Ballman KV, Fiveash JB, Uhm JH, Giannini C, Jaeckle KA, Geoffroy FJ, Nabors LB, Buckner JC; North Central Cancer Treatment Group.

Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1192-9. Epub 2006 Apr 19.

PMID:
16626884
10.

Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer.

Schild SE, Bonner JA, Shanahan TG, Brooks BJ, Marks RS, Geyer SM, Hillman SL, Farr GH Jr, Tazelaar HD, Krook JE, Geoffroy FJ, Salim M, Arusell RM, Mailliard JA, Schaefer PL, Jett JR.

Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):943-51.

PMID:
15234027
11.

Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer.

Perez EA, Geoffroy FJ, Hillman S, Johnson EA, Farr GH Jr, Tazelarr HD, Hatfield AK, Krook JE, Maillard JA, Levitt R, Marks RS.

Lung Cancer. 2004 Jun;44(3):347-53.

PMID:
15140548
12.

A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma.

George CM, Vogelzang NJ, Rini BI, Geoffroy FJ, Kollipara P, Stadler WM.

Ann Oncol. 2002 Jan;13(1):116-20.

PMID:
11863091
13.

Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells.

Grem JL, Nguyen D, Monahan BP, Kao V, Geoffroy FJ.

Biochem Pharmacol. 1999 Aug 1;58(3):477-86.

PMID:
10424768
14.

Relative frequencies and sites of presentation of lymphoid neoplasms in a community hospital according to the revised European-American classification.

Siebert JD, Mulvaney DA, Potter KL, Fishkin PA, Geoffroy FJ.

Am J Clin Pathol. 1999 Mar;111(3):379-86.

PMID:
10078114
15.

Modulation of fluorouracil cytotoxicity by interferon-alpha and -gamma.

Ismail A, Van Groeningen CJ, Hardcastle A, Ren Q, Aherne GW, Geoffroy F, Allegra CJ, Grem JL.

Mol Pharmacol. 1998 Feb;53(2):252-61.

16.

High affinity human antibodies by phage display.

Aujame L, Geoffroy F, Sodoyer R.

Hum Antibodies. 1997;8(4):155-68. Review.

PMID:
9395918
17.

Full-scale 'naïve' human antibody repertoires assembled from VH and VL variable regions.

Sodoyer R, Peubez I, Pion C, Dubayle J, Jacquemot P, Geoffroy F, Even J, Aujame L.

Hum Antibodies. 1997;8(1):37-42.

PMID:
9265504
18.

Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells.

Ren Q, Van Groeningen CJ, Hardcastle A, Aherne GW, Geoffroy F, Allegra CJ, Johnston PG, Grem JL.

Oncol Res. 1997;9(2):77-88.

PMID:
9167189
19.
20.

Effects of 9-aminocamptothecin on newly synthesized DNA in patient bone marrow samples.

Geoffroy F, Dahut W, Takimoto CH, Grem JL.

Clin Cancer Res. 1995 Nov;1(11):1345-51.

21.

Determinants of sensitivity to 1-beta-D-arabinofuranosylcytosine in HCT 116 and NCI-H630 human colon carcinoma cells.

Grem JL, Geoffroy F, Politi PM, Cuddy DP, Ross DD, Nguyen D, Steinberg SM, Allegra CJ.

Mol Pharmacol. 1995 Aug;48(2):305-15.

PMID:
7651364
22.

A new phage display system to construct multicombinatorial libraries of very large antibody repertoires.

Geoffroy F, Sodoyer R, Aujame L.

Gene. 1994 Dec 30;151(1-2):109-13.

PMID:
7828857
23.

Determinants of trimetrexate lethality in human colon cancer cells.

Grem JL, Voeller DM, Geoffroy F, Horak E, Johnston PG, Allegra CJ.

Br J Cancer. 1994 Dec;70(6):1075-84.

24.

Cytotoxicity and metabolism of 4-methoxy-8-(beta-D-ribofuranosylamino)pyrimido[5,4-d]pyrimidine in HCT 116 colon cancer cells.

Grem JL, Daychild P, Drake J, Geoffroy F, Trepel JB, Pirnia F, Allegra CJ.

Biochem Pharmacol. 1994 Nov 29;48(11):2117-26.

PMID:
7528507
25.

Chemotherapy of advanced gastrointestinal cancer.

Geoffroy F, Grem JL.

Curr Opin Oncol. 1994 Jul;6(4):427-34. Review.

PMID:
7803544
26.

Inactivation of human cytomegalovirus by sodium periodate oxidation.

Geoffroy F, Ogier G, Chantepie J, Quash G.

Arch Virol. 1994;135(1-2):61-74.

PMID:
8198450
27.

Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells.

Geoffroy FJ, Allegra CJ, Sinha B, Grem JL.

Oncol Res. 1994;6(12):581-91.

PMID:
7787251
28.

Effects of adrenal cortical steroids on calcium metabolism.

CLARK I, GEOFFROY F, BOWERS W.

Endocrinology. 1959 Jun;64(6):849-56. No abstract available.

PMID:
13652902
29.

[Assay of papain].

GAUTHIER B, CAPPELAERE J, GEOFFROY F.

Ann Pharm Fr. 1957 Jan;15(1):31-9. French. No abstract available.

PMID:
13435602

Supplemental Content

Loading ...
Support Center